{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T08:46:41Z","timestamp":1775810801534,"version":"3.50.1"},"reference-count":29,"publisher":"Korean Ophthalmological Society","issue":"2","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["ekjo.org"],"crossmark-restriction":true},"short-container-title":["Korean J Ophthalmol"],"published-print":{"date-parts":[[2026,4,5]]},"abstract":"<jats:p>Purpose: To evaluate functional and anatomical outcomes, including vessel morphology parameters on swept-source optical coherence tomography angiography (SS-OCTA), in eyes with neovascular age-related macular degeneration (nAMD) switched to brolucizumab.Methods: This retrospective study included 37 eyes with nAMD that were switched from other anti\u2013vascular endothelial growth factor (anti-VEGF) agents to intravitreal brolucizumab. Best-corrected visual acuity (BCVA), injection intervals, central subfield thickness (CST), pigment epithelial detachment (PED), and presence of retinal fluid were compared between baseline and 12 months after switch. SS-OCTA images were analyzed to quantify macular neovascularization (MNV) area, vessel density, fractal dimension (FD), and lacunarity.Results: Switching to brolucizumab significantly extended injection intervals and reduced CST, PED height and retinal fluid, while maintaining BCVA at 12 months. Quantitative OCTA analysis showed reductions in MNV area and FD following the switch. When compared with the preceding 12 months of other anti-VEGF therapy, FD still showed a significant reduction after brolucizumab treatment (p = 0.019). Intraocular inflammation occurred in one eye and resolved with topical corticosteroids.Conclusions: Intravitreal brolucizumab demonstrated favorable anatomical improvements and maintained visual outcomes over 12 months. Quantitative OCTA biomarkers, particularly FD, may serve as imaging indicators of disease activity and treatment response in eyes with nAMD undergoing a therapy switch.<\/jats:p>","DOI":"10.3341\/kjo.2025.0144","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T08:14:32Z","timestamp":1767860072000},"page":"159-168","update-policy":"https:\/\/doi.org\/10.3341\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Quantitative Optical Coherence Tomography Angiography Biomarkers Following a Switch to Brolucizumab in Neovascular Age-Related Macular Degeneration"],"prefix":"10.3341","volume":"40","author":[{"given":"Seungyeon","family":"Lee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaehwan","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seung-Young","family":"Yu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1893","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1264"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1001\/archopht.122.4.477"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23052592"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21218242"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2014-305327"},{"key":"ref6","first-page":"1751","volume-title":"Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials","author":"Maguire","year":"2016"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10132758"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2015.12.030"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2019.04.017"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2017.11.003"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1167\/tvst.9.3.18"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1159\/000503609"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-020-0936-7"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-023-03039-4"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-023-00445-0"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-022-05793-5"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1159\/000530544"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/ph16040562"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0205513"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3341\/kjo.2021.0085"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000002430"},{"key":"ref22","first-page":"2219","volume-title":"Optical coherence tomography angiography versus traditional multimodal imaging in assessing the activity of exudative age-related macular degeneration: a new diagnostic challenge","author":"Coscas","year":"2015"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1177\/1120672118759623"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-024-03007-2"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001628"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1097\/iae.0000000000001964"},{"key":"ref27","first-page":"2659714","volume-title":"Early OCT angiography changes of macular neovascularization in patients with exudative AMD treated with brolucizumab in a real-world setting","author":"Rubsam","year":"2022"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/aos.15242"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1177\/11206721221143154"}],"container-title":["Korean Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2025-0144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0144","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/ekjo.org\/upload\/pdf\/kjo-2025-0144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T07:48:33Z","timestamp":1775807313000},"score":1,"resource":{"primary":{"URL":"http:\/\/ekjo.org\/journal\/view.php?doi=10.3341\/kjo.2025.0144"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,5]]},"references-count":29,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.3341\/kjo.2025.0144","relation":{},"ISSN":["1011-8942","2092-9382"],"issn-type":[{"value":"1011-8942","type":"print"},{"value":"2092-9382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,5]]},"assertion":[{"value":"2025-10-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-08","order":2,"name":"published","label":"Published online","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-05","order":3,"name":"published","label":"Print publication","group":{"name":"publication_history","label":"Publication History"}}]}}